Combigene-foretradesemission-2021

About CombiGene AB

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.
Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market. The company’s Certified Advisor is FNCA Sweden AB.

CombiGene AB
Agavägen 52A
SE-181 55 Lidingö
Sweden

info@dev.combi.scratchcomm.se

Follow what's happening at CombiGene, subscribe to our newsletter.

Our privacy policy